Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,378.0
16.9 (0.50%)

 

  • STI Straits Times Index
    3,378.0
    16.9 (0.50%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,658.2
    9.3 (0.56%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,765.4
    303.7 (1.07%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,924.2
    23.0 (0.79%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,467.0
    420.8 (2.00%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,456.5
    53.2 (0.83%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,094.4
    27.8 (1.35%)
    Index delayed 20 minutes
  • XAO XAO
    6,786.2
    50.8 (0.75%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 951.8M
  • Value: 1,059.6M
  • Rise: 198
  • Fall: 120
  • Unch: 520

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Libra0.052+0.025
QT Vascular0.006+0.002
Sino Grandness0.050+0.004
SunMoonFood^0.063+0.005
Koh Eco0.058+0.001
G Invacom^0.137+0.005
Genting Sing0.920-
Sen Yue0.038-
Golden Agri-Res0.300-
TEE Intl0.102+0.001

World Indices

World Indices
Name Last Change
Nasdaq 8,146.5 -60.8
HSI 28,765.4 +303.7
HSCEI 10,909.4 +124.9
Jakarta 6,456.5 +53.2
Nikkei 225 21,467.0 +420.8
SSE Comp 2,924.2 +23.0
Shanghai A 3,062.8 +24.1
Shanghai B 290.0 +1.3
ShenZhen A 1,631.7 +12.2
ShenZhen B 972.3 +3.6
Taiwan W 10,873.2 +73.9
PSE Comp 0.0
KOSPI 2,094.4 +27.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CYNATA THERAPEUTICS LTD CYNATA THERAPEUTICS
Updated on 19 Jul 2019 (End of trading day)
Last (AUD): 1.740 Change: +0.140 High: 1.850 Remarks: -
Change (%): +8.75 Low: 1.740
Open 1.825 Yesterday's Close 1.6
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 923,537 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.04482 Trailing EPS (AUD) e -0.05625 NAV (AUD) b 0.1502
PE a - Trailing PE f - Price / NAV b 11.5846
Dividend (AUD) d - Cash In Hand (AUD) g 0.1044 Issued & Paid-up Shares c 101,885,000
Dividend Yield (%) d - Price / Cash In Hand g 16.667 Treasury Shares h -
Beta - 75 Daysi 0.987 R-Squared - 75 Days(%)i 2.14 Market Cap (M) 177.280
Beta - 500 Daysi 0.569 R-Squared - 500 Days (%)i 0.87 Enterprise Value (M) 166.640
Piotroski F Score 1 Exchange Code CYP Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 57.80 Free Float (%) 77.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 08 May 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CYNATA THERAPEUTICS LTD ASX 177.280 - - 11.5846 -
Industry Biotechnology ASX 2,062.569 55.250 52.165 13.1881 0.963
Local Peer CSL ASX 101,856.584 45.649 41.810 14.7785 1.014
Local Peer POLYNOVO LIMITED ASX 1,087.490 - - 40.2200 -
Local Peer AVITA MEDICAL LTD ASX 814.015 - - 26.0479 -
Local Peer MESOBLAST LTD ASX 722.934 - - 1.0251 -
Local Peer NEXT SCIENCE LTD ASX 697.994 - - - -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 498.070 - - 10.3957 -
Local Peer TELIX PHARMACEUTIC ASX 363.579 - - 6.8716 -
Local Peer NEUREN PHARMACEUTICALS LTD ASX 145.470 47.331 47.338 5.8971 -
Local Peer RESAPP HEALTH LIMITED ASX 107.920 - - 11.5672 -
Local Peer IMMUTEP LTD ASX 75.160 - - 2.2340 -
Local Peer PHYLOGICA LIMITED ASX 65.957 - - 7.1053 -
Local Peer ORTHOCELL LIMITED ASX 67.551 - - 25.1429 -
Other Local Peers IMUGENE LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), ZELDA THERAPEUTICS LTD (ASX), RHINOMED LIMITED (ASX), BIOTRON (ASX), MEMPHASYS LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), ADALTA LTD (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), PATRYS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), IMMURON LIMITED (ASX), BIONOMICS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), REGENEUS LTD (ASX), CELLMID LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), ACTINOGEN MEDICAL LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), CCP TECHNOLOGIES LTD (ASX), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NOVITA HEALTHCARE LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), MEDIBIO LIMITED (ASX), BPH ENERGY LIMITED (ASX), ALCHEMIA LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX)
Global Peer AMGEN INC NASDAQ 108,806.483 12.962 13.474 10.0449 3.055
Global Peer GILEAD SCIENCES INC NASDAQ 82,702.262 15.161 14.036 3.7676 3.534
Global Peer AMGEN-T HKEx 609,936.000 9.271 9.631 7.1731 4.272
Global Peer CELGENE CORP NASDAQ 63,614.452 15.723 13.407 7.7911 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 44,598.350 21.274 20.697 9.4422 -
Global Peer BIOGEN INC NASDAQ 44,841.634 10.121 9.609 3.2424 -
Global Peer ILLUMINA INC NASDAQ 43,100.400 52.180 50.647 10.8157 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,684.289 13.371 13.464 3.4606 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,087.830 349.072 65.052 2.7907 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 21,708.719 68.699 19.435 4.2359 0.873
Other Global Peers INCYTE CORPORATION (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), SEATTLE GENETICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), MODERNA INC (NASDAQ), 3SBIO (HKEx), Lonza (SGX), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), TILRAY INC (NASDAQ), FIBROGEN INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), LIGAND PHARMACEUTICAL INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), INSMED INC (NASDAQ), NATERA INC (NASDAQ), REGENXBIO INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ANAPTYSBIO INC (NASDAQ), VERACYTE INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), OPKO HEALTH INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), INTREXON CORP (NASDAQ), EDITAS MEDICINE INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), CORTEXYME INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), RADIUS HEALTH INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), HAOHAI BIOTEC (HKEx), NGM BIOPHARMACEUTICALS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), FRONTAGE (HKEx), KURA ONCOLOGY INC (NASDAQ), RETROPHIN INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), VIVA BIOTECH (HKEx), ALDER BIOPHARMACEUTICALS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ASCLETIS-B (HKEx), ARVINAS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), OMEROS CORP (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), VANDA PHARMACE INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), PERSONALIS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), SYNTHORX INC (NASDAQ), ESSEX BIO-TECH (HKEx), KODIAK SCIENCES INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), TRANSLATE BIO INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), PROTHENA CORP PLC (NASDAQ), NEXTCURE INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), RESTORBIO INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERUS B V (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), IMMUNOGEN INC (NASDAQ), AGENUS INC (NASDAQ), KADMON HLDGS INC (NYSE), ACHILLION PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), XBIOTECH INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), GERON CORP (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), RECRO PHARMA INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), CHIASMA INC (NASDAQ), AFFIMED N V (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AXCELLA HEALTH INC (NASDAQ), CHIMERIX INC (NASDAQ), STANDARD DIVERSIFIED INC (NYSE American), MERSANA THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), AXOVANT GENE THERAPIES LTD (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), ARDELYX INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), ALDEYRA THERAPEUTICS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), IMV INC (NASDAQ), PFENEX INC (NYSE American), BBI LIFE SCI (HKEx), TOCAGEN INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), BIOTIME INC (NYSE American), SESEN BIO INC (NASDAQ), NANTKWEST INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), HEMISPHERX BIOPHARMA INC (NYSE American), ADURO BIOTECH INC (NASDAQ), VERASTEM INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), UNI-BIO GROUP (HKEx), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), NOVAVAX INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), INMUNE BIO INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), EQUILLIUM INC (NASDAQ), TREVENA INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), INFINITY PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SAVARA INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), PORT (SET), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), INFLARX N V (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), VERMILLION INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ORGENESIS INC (NASDAQ), CURIS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), OUTLOOK THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), IBIO INC (NYSE American), COHBAR INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), ARAVIVE INC (NASDAQ), CEL-SCI CORP (NYSE American), CT ENTERPRISE (HKEx), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), REGENT PACIFIC (HKEx), OPIANT PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), ZAFGEN INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), EVOGENE LTD (NASDAQ), CONTRAFECT CORP (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), SENESTECH INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), EXTRAWELL PHAR (HKEx), BIONANO GENOMICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), ONCOLYTICS BIOTECH INC (NASDAQ), ORAGENICS INC (NYSE American), ISORAY INC (NYSE American), HEAT BIOLOGICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SOLIGENIX INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), BIOCEPT INC (NASDAQ), HISTOGENICS CORP (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CAPRICOR THERAPEUTICS INC (NASDAQ), PRECIPIO INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), VICAL INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), NANOVIRICIDES INC (NYSE American), OHR PHARMACEUTICAL INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ATYR PHARMA INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), CONATUS PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), Suntar Eco-City^ (SGX), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ADVAXIS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), NEURALSTEM INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), QT Vascular (SGX), HAO WEN HLDGS (HKEx), MGRC (Bursa), MEGASUN (Bursa), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), OPGEN INC (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.320
+22.54 %
10 Days -+0.460
+35.94 %
20 Days -+0.500
+40.32 %
Medium Term Return 3 Months -+0.530
+43.80 %
6 Months -+0.380
+27.94 %
1 Year -+0.460
+35.94 %
Long Term Return 2 Years -+1.135
+187.60 %
3 Years -+1.410
+427.27 %
5 Years -+1.330
+324.39 %
Annualised Return Annualised --
+33.52 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.940 - 1.850 Change From 1 Year Low +0.800 % Change From 1 Year Low (%) +85.11
Change From 1 Year High -0.110 % Change From 1 Year High (%) -5.95
2 Years Range 0.525 - 1.850 Change From 2 Years Low +1.215 % Change From 2 Years Low (%) +231.43
Change From 2 Years High -0.110 % Change From 2 Years High (%) -5.95
5 Years Range 0.225 - 1.850 Change From 5 Years Low +1.515 % Change From 5 Years Low (%) +673.33
Change From 5 Years High -0.110 % Change From 5 Years High (%) -5.95
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on therapeutic stem cell platform technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
19 Jul 2019 1.825 1.850 1.740 1.740 923,537 -
18 Jul 2019 1.600 1.600 1.600 1.600 - -
17 Jul 2019 1.475 1.620 1.475 1.600 122,495 -
16 Jul 2019 1.475 1.620 1.475 1.600 122,495 -
15 Jul 2019 1.480 1.540 1.410 1.430 169,628 -
12 Jul 2019 1.300 1.420 1.300 1.420 204,904 -
11 Jul 2019 1.250 1.285 1.240 1.285 101,810 -
10 Jul 2019 1.250 1.255 1.180 1.255 108,198 -
09 Jul 2019 1.250 1.260 1.210 1.230 70,458 -
08 Jul 2019 1.245 1.270 1.220 1.220 55,447 -
05 Jul 2019 1.275 1.280 1.255 1.280 24,924 -
04 Jul 2019 1.280 1.280 1.270 1.275 31,258 -
03 Jul 2019 1.240 1.270 1.240 1.270 29,395 -
02 Jul 2019 1.245 1.255 1.240 1.240 39,843 -
01 Jul 2019 1.240 1.250 1.225 1.250 62,836 -
28 Jun 2019 1.250 1.260 1.245 1.245 28,429 -
27 Jun 2019 1.255 1.260 1.240 1.260 4,984 -
26 Jun 2019 1.260 1.260 1.250 1.255 113,702 -
25 Jun 2019 1.250 1.250 1.225 1.245 76,412 -
24 Jun 2019 1.240 1.240 1.175 1.230 97,330 -
21 Jun 2019 1.250 1.250 1.215 1.240 83,441 -
20 Jun 2019 1.245 1.245 1.210 1.240 21,389 -
Summary
Current 2 Weeks
(08 Jul 2019 to 19 Jul 2019)
1.245 1.850 1.180 1.740 1,878,972 -
Previous 2 Weeks
(24 Jun 2019 to 05 Jul 2019)
1.240 1.850 1.175 1.280 509,113 -
4 Weeks from
(24 May 2019 to 21 Jun 2019)
1.200 1.850 1.160 1.240 1,378,028 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.